{"nctId":"NCT02308033","briefTitle":"Multi-Center Study of New Medications to Treat Vaginal Infections","startDateStruct":{"date":"2015-06","type":"ACTUAL"},"conditions":["Vaginal Infection"],"count":204,"armGroups":[{"label":"Metronidazole vaginal gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metronidazole"]},{"label":"Gel vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Gel vehicle"]}],"interventions":[{"name":"Metronidazole","otherNames":[]},{"name":"Gel vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:\n* Capable of providing written informed consent or assent\n* Currently not menstruating and not anticipating menses during treatment\n* If heterosexually active, subject must be post-menopausal for â‰¥ 1 year, surgically sterile, or practicing an acceptable form of birth control\n* Negative pregnancy test\n* Other criteria as identified in the protocol\n\nExclusion Criteria:\n\n* Other infectious causes of vulvovaginitis\n* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products\n* Nursing mother\n* Use of any investigational drug within 30 days of enrollment\n* History of hypersensitivity to any ingredient/component of the formulations\n* Other criteria as identified in the protocol","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit","description":"The percentage of participants with clinical cure in each arm was compared. Clinical cure of bacterial vaginosis is defined as 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine \"fishy\" odor, 3. the saline wet mount is \\<20% clue cells","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement of BV Clue Cells","description":"Clue cells on wet mount were assessed and categorized as absent (\\<20%) or present (\\>=20%). Absence of clue cells is associated with improvement. The comparison was for percentage between arms for clue cells absent (\\<20%).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"58","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiologic Improvement/Cure","description":"For bacterial vaginosis (BV), Gram stain Nugent scores are catergized as normal (0 to 3), intermediate (4 to 6) or BV (7 to 10). Normal scores are associated with BV microbiologic cure. The percentage of participants with normal scores were compared between treatments.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"59","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit","description":"Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events","description":"Adverse events were collected at study visits, from subject diaries and from spontaneous reports","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":96},"commonTop":["Vulvovaginal pruritis","Vulvovaginal candidiasis","Headache","Vulvovaginal mycotic infection"]}}}